FAQ on Immunic Inc.'s $5.1M Registered Direct Offering and Its Implications

What is the purpose of Immunic Inc.’s registered direct offering?

The purpose of the registered direct offering is to secure approximately $5.1 million in gross proceeds to fund Immunic Inc.’s clinical trials and operations, as well as for other general corporate purposes.

Who led the registered direct offering for Immunic Inc.?

Aberdeen Investments led the registered direct offering for Immunic Inc.

How many shares were offered and at what price?

Immunic Inc. offered 5,666,667 shares of its common stock, each at a price of $0.90.

Who acted as the sole placement agent for the offering?

Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.

What is Immunic Inc.’s lead development program?

Immunic Inc.’s lead development program is vidofludimus calcium (“IMU-838”), currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively.

Where can I find more information about Immunic Inc.?

For further information, visit the company’s website at www.IMUX.com.

What are the potential applications of IMU-856?

IMU-856 is intended to restore intestinal barrier function and regenerate bowel epithelium, potentially applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, graft-versus-host-disease (“GvHD”), and weight management.

What is the significance of Immunic Inc.’s registered direct offering?

The registered direct offering is significant as it provides Immunic Inc. with the necessary funds to advance its clinical trials and operations, supporting the development of therapies for chronic inflammatory and autoimmune diseases.